House Appropriators Call For CMS To Pay More For Domestic Generic Drugs And Biosimilars
Executive Summary
Committee report sets manufacturing reshoring agenda for CMS and other HHS agencies like BARDA and ASPR that includes piloting new payment and reimbursement policies, strengthening domestic API production capabilities, and developing more flexible pharmaceutical manufacturing technologies that could add surge capacity.